ConductScience.org, home

Paper17568824

Management of chronic hepatitis C: consensus guidelines.

Sherman M and 9 others. Can J Gastroenterol, 2007. Cited by 83 papers, by iCite.

Cite this record

ConductScience Library. Management of chronic hepatitis C: consensus guidelines. Papers, record 17568824. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17568824

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of chronic hepatitis C: consensus guidelines.
PubMed
Journal
Can J Gastroenterol
PubMed
Year
2007
PubMed
Publication types
Consensus Statement, Journal Article
PubMed
Citations, by iCite
83
iCite
Relative citation ratio, by iCite
2.4
iCite
Revised in PubMed
2026-03-04
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sherman MMorris
2Shafran SStephen
3Burak KKelly
4Doucette KKaren
5Wong WWinnie
6Girgrah NNigel
7Yoshida EEric
8Renner EEberhard
9Wong PPhilip
10Deschênes MMarc

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis CMajor topic
Canada
Humans

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01095445EXtended Therapy in Hepatitis C Genotype 3 Infected PatientsBackground

Source ClinicalTrials.gov

Download CSV of trials

References89

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117033526Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.J Pediatr Gastroenterol Nutr2006https://conductscience.org/library/papers/17033526PubMed
216767309Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.Braz J Infect Dis2006https://conductscience.org/library/papers/16767309PubMed
315940780Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.J Rheumatol2005https://conductscience.org/library/papers/15940780PubMed
416234288Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C.Nephrol Dial Transplant2006https://conductscience.org/library/papers/16234288PubMed
512407571National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.Hepatology2002https://conductscience.org/library/papers/12407571PubMed
615558712Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.Hepatology2004https://conductscience.org/library/papers/15558712PubMed
77698595American Gastroenterological Association Medical Position Statement: guidelines for the use of enteral nutrition.Gastroenterology1995https://conductscience.org/library/papers/7698595PubMed
811848726Surprisingly small effect of antiviral treatment in patients with hepatitis C.Ann Intern Med2002https://conductscience.org/library/papers/11848726PubMed
915751068PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.Arthritis Rheum2005https://conductscience.org/library/papers/15751068PubMed
1015768339Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.Clin Infect Dis2005https://conductscience.org/library/papers/15768339PubMed
1112962779Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha2b monotherapy.Transplant Proc2003https://conductscience.org/library/papers/12962779PubMed
1215273266Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.J Urban Health2004https://conductscience.org/library/papers/15273266PubMed
1315972867Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.N Engl J Med2005https://conductscience.org/library/papers/15972867PubMed
1416709661Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.Gut2006https://conductscience.org/library/papers/16709661PubMed
1515239094A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.Hepatology2004https://conductscience.org/library/papers/15239094PubMed
1616025497Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.Hepatology2005https://conductscience.org/library/papers/16025497PubMed
1716530503Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.Gastroenterology2006https://conductscience.org/library/papers/16530503PubMed
1816630037Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.HIV Med2006https://conductscience.org/library/papers/16630037PubMed
1917162319Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia.HIV Clin Trials2006https://conductscience.org/library/papers/17162319PubMed
2015826710Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.J Hepatol2005https://conductscience.org/library/papers/15826710PubMed

See all 89 referencesDownload CSV of references

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.

PMIDTitleJournalYearIn PapersSource
42872224Trends in chronic hepatitis C visits by providers in Quebec, Canada: A population-level cohort study.Can Liver J2026https://conductscience.org/library/papers/42872224PubMed
37040993Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.CMAJ2023https://conductscience.org/library/papers/37040993PubMed
35989890Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT).Can Liver J2021https://conductscience.org/library/papers/35989890PubMed
35787600
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Med Sci Monit2022https://conductscience.org/library/papers/35787600PubMed
33173710Assessing State Variation in Plastic Surgeons' Risk of Hepatitis C Exposure: Revisit in Methodology.Plast Reconstr Surg Glob Open2020https://conductscience.org/library/papers/33173710PubMed
30705482Prevalence and genotyping pattern of hepatitis C virus among patients on maintenance hemodialysis at five centers in Pune, India.Med J Armed Forces India2019https://conductscience.org/library/papers/30705482PubMed
29769873Hepatitis C surveillance in Canada.Can Commun Dis Rep2014https://conductscience.org/library/papers/29769873PubMed
29557047Let's Talk About B: Barriers to Hepatitis B Screening and Vaccination Among Asian and South Asian Immigrants in British Columbia.J Racial Ethn Health Disparities2018https://conductscience.org/library/papers/29557047PubMed
26851949Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.Eur J Clin Microbiol Infect Dis2016https://conductscience.org/library/papers/26851949PubMed
25583667Cost-effectiveness of screening for hepatitis C in Canada.CMAJ2015https://conductscience.org/library/papers/25583667PubMed
25278674Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.World J Gastroenterol2014https://conductscience.org/library/papers/25278674PubMed
24948971Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children.Pak J Med Sci2014https://conductscience.org/library/papers/24948971PubMed
24782620Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.World J Gastroenterol2014https://conductscience.org/library/papers/24782620PubMed
24696622The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.Hepat Med2013https://conductscience.org/library/papers/24696622PubMed
24212914Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia.Can J Gastroenterol Hepatol2014https://conductscience.org/library/papers/24212914PubMed
24205255Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.PLoS One2013https://conductscience.org/library/papers/24205255PubMed
23781516The epidemiology of hepatitis C in a Canadian Indigenous population.Can J Gastroenterol2013https://conductscience.org/library/papers/23781516PubMed
23714158The metabolomic window into hepatobiliary disease.J Hepatol2013https://conductscience.org/library/papers/23714158PubMed
23517633Hepatitis C and the surgeon.Can J Surg2013https://conductscience.org/library/papers/23517633PubMed
23509527Pharmacists and harm reduction: A review of current practices and attitudes.Can Pharm J (Ott)2012https://conductscience.org/library/papers/23509527PubMed

See all 54 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17568824

GET https://conductscience.org/api/papers/v1/17568824/references?page=2